Cutaneous delivery of prophylactic and therapeutic vaccines: Historical perspective and future outlook

Expert Review of Vaccines

Volumn 7, Issue 9, 2008, Pages 1329-1339

  Mikszta, John A ^a   Laurent, Philippe E ^b  

^a BD Technologies   (United States)

^b BD Medical Pharmaceutical Systems   (France)

Author keywords

Cutaneous; Immune compromised; Intradermal; Microneedle; Skin; Vaccine

Indexed keywords

CANCER VACCINE; HEPATITIS B VACCINE; INFLUENZA VACCINE; NASAFLU; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; BELL PALSY; CANCER PATIENT; CELLULAR IMMUNITY; DEVICE; DRUG DELIVERY SYSTEM; DRUG MEGADOSE; GOOD CLINICAL PRACTICE; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HEPATITIS B; HIGH RISK POPULATION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; INFLUENZA; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MICRONEEDLE; NEEDLE; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SCANNING ELECTRON MICROSCOPY; SKIN; SYRINGE; TUBERCULIN TEST;

ADMINISTRATION, CUTANEOUS; CANCER VACCINES; HUMANS; VIRAL VACCINES;

EID: 55849113292     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.9.1329     Document Type: Review

References (124)

1. Henderson DA, Borio LL, Grabenstein JD. Smallpox and vaccinia. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, Amsterdam, The Netherlands 773-803 (2008).
2. Weniger BG, Papania MJ. Alternative vaccine delivery methods. In: Vaccines (5th Edition). Plotkin SA, Orenstein WA, Offit PA (Eds). Elsevier, Amsterdam, The Netherlands, 1357-1392 (2008). •• Extraordinarily comprehensive review on vaccine delivery methods of the past, present and future.
3. Babiuk S, Baca-Estrada M, Babiuk LA, Ewen C, Foldvari M. Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery. J. Control Release 66, 199-214 (2000).
4. Larregina AT, Falo LD. Changing paradigms in cutaneous immunology: adapting with dendritic cells. J. Invest. Dermatol. 124, 1-12 (2005).
5. Randolph GJ, Angeli V, Swartz MA. Dendritic-cell trafficking to lymph nodes through lymphatic vessels. Nature Rev. Immunol. 5, 617-628 (2005).
6. Reddy ST, van der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nature Biotechnol. 25, 1159-1164 (2007).
7. Cardell K, Fryden A, Normann B. Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise. Scand. J. Infect. Dis. 31, 197-200 (1999).
8. Carlsson T, Struve J, Sonnerborg A, Weiland O. The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination. Scand. J. Infect. Dis. 31, 93-95 (1999).
9. Egemen A, Aksit S, Kurugol Z, Erensoy S, Bilgic A, Akilli M. Low-dose intradermal versus intramuscular administration of recombinant hepatitis B vaccine: a comparison of immunogenicity in infants and preschool children. Vaccine 16, 1511-1515 (1998).
10. Ghabouli MJ, Sabouri AH, Shoeibi N, Bajestan SN, Baradaran H. High seroprotection rate induced by intradermal administration of a recombinant hepatitis B vaccine in young healthy adults: comparison with standard intramuscular vaccination. Eur. J. Epidemiol. 19, 871-875
11. Henderson EA, Louie TJ, Ramotar K, Ledgerwood D, Hope KM, Kennedy A. Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers. Infect. Control Hosp. Epidemiol. 21, 264-269 (2000).
12. Jaiswal SP, Asolkar MV, Vijayvargiya R, Chitnis DS. Immunogenicity of low-dose hepatitis-B vaccine by the intradermal route and persistence of anti-HBs after 3 years. Indian J. Med. Res. 102, 129-133 (1995).
13. Kurugol Z, Erensoy S, Aksit S, Egemen A, Bilgic A. Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study. Vaccine 19, 3936-3939 (2001).
14. Kyi KP, Oo KM, Htun MM et al. Clinical trial of the intradermal administration of hepatitis B vaccine produced at the Department of Medical Research, Myanmar. Vaccine 20, 1649-1652 (2002).
15. Levitz RE, Cooper BW, Regan HC. Immunization with high-dose intradermal recombinant hepatitis-B vaccine in health-care workers who failed to respond to intramuscular vaccination. Infect. Control Hosp. Epidemiol. 16, 88-91 (1995).
16. Playford EG, Hogan PG, Bansal AS et al. Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine. Infect. Control Hosp. Epidemiol. 23, 87-90 (2002).
17. Rahman F, Dahmen A, Herzog-Hauff S, Bocher WO, Galle PR, Lohr HF. Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31, 521-527 (2000).
18. Struve J, Aronsson B, Frenning B, Forsgren M, Weiland O. Response to a booster dose 18 months after a low anti-HBs response (10-99 IU/l) to 3 doses of intradermally or intramuscularly administered recombinant hepatitis-B vaccine. Infection 23, 42-45 (1995).
19. Yamashiki M, Kosaka Y, Nishimura A. An effective intradermal hepatitis B vaccination. Vaccine 15, 1618-1623 (1997).
20. Zhuang GH, Yan H, Wang XL et al. Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory. Vaccine 24, 2186-2192 (2006).
21. Angelico M, Di Paolo D, Trinito MO et al. Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis. Hepatology 35, 176-181 (2002).
22. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am. J. Kidney Dis. 36, 976-982 (2000).
23. Chau KF, Cheng YL, Tsang DNC et al. Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination. Am. J. Kidney Dis. 43, 910-917 (2004).
24. Choy BY, Peiris JSM, Chan TM, Lo SKF, Lui SL, Lai KN. Immunogenicity of intradermal hepatitis B vaccination in renal transplant recipients. Am. J. Transplant. 2, 965-969 (2002).
25. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol. Dialysis Transplant. 12, 1204-1211 (1997).
26. Fabrizi F, Dixit V, Magnini M, Elli A, Martin P. Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease. Aliment. Pharmacol. Ther. 24, 497-506 (2006).
27. Karahocagil MK, Buzgan T, Irmak H, Karsen H, Akdeniz H, Akman N. Comparison of intramuscular and intradermal applications of hepatitis B vaccine in hemodialysis patients. Renal Failure 28, 561-565 (2006).
28. Mettang T, Schenk U, Thomas S et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure - a preliminary study. Nephron 72, 192-196 (1996).
29. Morais EO, Resende MR, Oliveira AM et al. Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up. Aliment. Pharmacol. Ther. 25, 849-855 (2007).
30. Propst T, Propst A, Lhotta K, Vogel W, Konig P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. Am. J. Kidney Dis. 32, 1041-1045 (1998). • One of the first investigators to propose a high-dose intradermal hepatitis B immunization regimen for dialysis patients and to show benefits over the same dose administered by intramuscular injection.
31. Vlassopoulos D, Arvanitis D, Lilis D, Hatjiyannakos D, Louizou K, Hadjiconstantinou V. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Renal Failure 19, 455-460 (1997).
32. Vlassopoulos DA, Arvanitis DK, Lilis DS, Louizou KI, Hadjiconstantinou VE. Lower long-term efficiency of intradermal hepatitis B vaccine compared to the intramuscular route in hemodialysis patients. Int. J. Art. Organs 22, 739-743 (1999).
33. Waite NM, Thomson LG, Goldstein MB. Successful vaccination with intradermal hepatitis-B vaccine in hemodialysis-patients previously nonresponsive to intramuscular hepatitis-B vaccine. J. Amer. Soc. Nephrol. 5, 1930-1934 (1995).
34. Nagafuchi S, Kashiwagi S, Imayama S, Hayashi J, Niho Y. Intradermal administration of viral vaccines. Rev. Med. Virol. 8, 97-111 (1998).
35. Scuffham PA, West PA. Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20, 2562-2578 (2002).
36. Vajdy M, Baudner B, Del Giudice G, O'Hagan D. A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza. Clin. Immunol. 123, 166-175 (2007).
37. Brooks JH, Criep LH, Ruben FL. Intradermal administration of bivalent and monovalent influenza vaccines. Ann. Allergy 39, 110-112 (1977).
38. Brown H, Kasel JA, Freeman DM, Moise LD, Grose NP, Couch RB. The immunizing effect of influenza A/New Jersey/76 (Hsw1N1) virus vaccine administered intradermally and intramuscularly to adults. J. Infect. Dis. 136 Suppl. S466-S471 (1977).
39. Halperin W, Weiss WI, Altman R et al. A comparison of the intradermal and subcutaneous routes of influenza vaccination with A/New Jersey/76 (swine flu) and A/Victoria/75: report of a study and review of the literature. Am. J. Pub. Health 69, 1247-1250 (1979).
40. Herbert FA, Larke RP, Markstad EL. Comparison of responses to influenza A/New Jersey/76-A/Victoria/75 virus vaccine administered intradermally or subcutaneously to adults with chronic respiratory disease. J. Infect. Dis. 140, 234-238 (1979).
41. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286-2294 (2004). • Reinvigorated the field and has led to a greatly increased interest in re-exploring the intradermal route of delivery for influenza vaccine.
42. Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. Dose sparing with intradermal injection of influenza vaccine. N. Engl. J. Med. 351, 2295-2301 (2004). • Reinvigorated the field and has led to a greatly increased interest in re-exploring the intradermal route of delivery for influenza vaccine.
43. Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 25, 659-663 (2006).
44. Chiu SS, Peiris JSM, Chan KH, Wong WHS, Lau YL. Immunogenicity and safety of intradermal influenza immunization at a reduced dose in healthy children. Pediatrics 119, 1076-1082 (2007).
45. Belshe RB, Newman FK, Wilkins K et al. Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25, 6755-6763 (2007). • Much-anticipated follow-up to the 2004 publication, this time including the critical low-dose intramuscular control group.
46. Booy R, Weber F, Saville M. Immunogenicity of a novel influenza vaccine delivered by intradermal microinjection in over 60-year-olds. Presented at: Options for the Control of Influenza VI. Toronto, Canada, 17-23 June 2007. • New injection technique and device for intradermal delivery of influenza vaccine.
47. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198(5), 650-658 (2008). • New injection technique and device for intradermal delivery of influenza vaccine.
48. Alfonso M, Diaz A, Hernandez AM et al. An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J. Immunol. 168, 2523-2529 (2002).
49. Berd D, Sato T, Maguire HC, Kairys J, Mastrangelo MJ. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22, 403-415 (2004).
50. Dessureault S, Noyes D, Lee D et al. A Phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease. Ann. Surg. Oncol. 14, 869-884 (2007).
51. Hunger RE, Brand CU, Streit M et al. Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant. Exp. Dermatol. 10, 161-167 (2001).
52. Kruit WHJ, van Ojik HH, Brichard VG et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int. J. Cancer 117, 596-604 (2005).
53. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13, 905-918 (2006). • One of very few studies comparing T-cell responses in cancer patients treated by intradermal or intranodel routes of administration.
54. O'Rourke MGE, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52, 387-395 (2003).
55. Salcedo M, Bercovici N, Taylor R et al. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol. Immunother. 55, 819-829 (2006).
56. Schreiber S, Kampgen E, Wagner E et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2 transfected cancer cells: outcome of a Phase I study. Hum. Gene Ther. 10, 983-993 (1999).
57. + T-cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol. Immunother. 55, 469-474 (2006).
58. Brunsvig PF, Aamdal S, Gjertsen MK et al. Telomerase peptide vaccination: a Phase I/II study in patients with non-small cell lung cancer. Cancer Immunol. Immunother. 55, 1553-1564 (206).
59. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11, 3017-3024 (2005).
60. Nemunaitis J, Sterman D, Jablons D et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J. Natl Cancer Inst. 96, 326-331 (2004).
61. Butterfield LH, Ribas A, Dissette VB et al. A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four α-fetoprotein peptides. Clin. Cancer Res. 12, 2817-2825 (2006).
62. Butterfield LH, Ribas A, Meng WS et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from a-fetoprotein in patients with hepatocellular cancer. Clin. Cancer Res. 9, 5902-5908 (2003).
63. Bernhardt SL, Gjertsen MK, Trachsel S et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating Phase I/II study. Br. J. Cancer 95, 1474-1482 (2006).
64. Gjertsen MK, Buanes T, Rosseland AR et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450 (2001).
65. Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neurooncology 6, 236-246 (2004).
66. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115, 3623-3633 (2005).
67. Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: Phase III, randomised controlled trial. Lancet 363, 594-599 (2004).
68. Oosterwijk-Wakka JC, Tiemessen DM, Bleumer I et al. Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase 1 study. J. Immunother. 25, 500-508 (2002).
69. Pandha HS, John RJ, Hutchinson J et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. Br. J. Urol. Int. 94, 412-418 (2004).
70. Simons JW, Jaffee EM, Weber CE et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res. 57, 1537-1546 (1997).
71. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63, 2127-2133 (2003).
72. Disis ML, Grabstein KH, Sleath PR, Cheever MA. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine. Clin. Cancer Res. 5, 1289-1297 (1999).
73. Guthmann MD, Castro MA, Cinat G et al. Cellular and humoral immune response to N-glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J. Immunother. 29, 215-223 (2006).
74. 2+ breast cancer following vaccination against Her2. J. Transl. Med. 5, 42 (2007).
75. + patients with metastatic breast and ovarian cancer. Clin. Cancer Res.8, 3407-3418 (2002).
76. Nicholson S, Bomphray CC, Thomas H et al. A Phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunol. Immunother. 53, 809-816 (2004).
77. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259 (2001). • Both cell-mediated and humoral immune responses were compared for a cancer vaccine administered by various routes of delivery.
78. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J. Clin. Invest. 109, 409-417 (2002).
79. Kyte JA, Gaudernack G. Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells. Cancer Immunol. Immunother. 55, 1432-1442 (2006).
80. Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11, 4469-4478 (2005).
81. Mincheff M, Tchakarov S, Zoubak S et al. Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur. Urol. 38, 208-217 (2000).
82. Perambakam S, Hallmeyer S, Reddy S et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother. 55, 1033-1042 (2006).
83. + T cell responses in patients with metastatic prostate cancer. J. Immunol. 174, 3798-3807 (2005).
84. Oki Y, McLaughlin P, Fayad LE et al. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Cancer 109, 77-83 (2007).
85. Bertinetti C, Zirlik K, Heining-Mikesch K et al. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression. Cancer Res. 66, 4496-4502 (2006).
86. Mosolits S, Markovic K, Frodin JE et al. Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin. Cancer Res. 10, 5391-5402 (2004).
87. Lomas M, Liauw W, Packham D et al. Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Ann. Oncol. 15, 324-329 (2004).
88. Nair S, McLaughlin C, Weizer A et al. Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. J. Immunol. 171, 6275-6282 (2003). • Study showed the impact of skin-administered adjuvants on dendritic cell migration and immune response.
89. Morse MA, Deng YP, Coleman D et al. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 5, 1331-1338 (1999).
90. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59, 56-58 (1999).
91. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 18, 899-906 (1999).
92. Mutsch M, Zhou WG, Rhodes P et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N. Engl. J. Med. 350, 896-903 (2004).
93. Glenn GM, Flyer DC, Ellingsworth LR et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev. Vaccines 6, 809-819 (2007).
94. Godefroy S, Peyre A, Garcia N, Muller S, Sesardic D, Partidos CD. Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM197 of diphtheria toxin. Infect. Immun. 73, 4803-4809 (2005).
95. Cui Z, Mumper RJ. Topical immunization using nanoengineered genetic vaccines. J. Control. Release 81, 173-184 (2002).
96. Shi ZK, Curiel DT, Tang DC. DNA-based non-invasive vaccination onto the skin. Vaccine 17, 2136-2141 (1999).
97. Vyas SP, Khatri K, Mishra V. Vesicular carrier constructs for topical immunisation. Exp. Opin. Drug Del. 4, 341-348 (2007).
98. Glenn GM, Villar CP, Flyer DC et al. Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum. Infect. Immun. 75, 2163-2170 (2007).
99. Frerichs DM, Ellingsworth LR, Frech SA et al. Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch. Vaccine 26, 2782-2787 (2008).
100. Dean CH, Alarcon JB, Waterston AM et al. Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax-JE) in non-human primates. Hum. Vacc. 1, 106-111 (2005).
101. Mikszta JA, Alarcon JB, Brittingham JM, Sutter DE, Pettis RJ, Harvey NG. Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery. Nature Med. 8, 415-419 (2002).
102. Mikszta JA, Sullivan VJ, Dean C et al. Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms. J. Infect. Dis. 191, 278-288 (2005).
103. Wermeling DP, Banks SL, Huclson DA et al. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc. Natl Acad. Sci. USA 105, 2058-2063 (2008).
104. Prausnitz MR. Microneedles for transdermal drug delivery. Adv. Drug Del. Rev. 56, 581-587 (2004).
105. Tezel A, Paliwal S, Shen ZC, Mitragotri S. Low-frequency ultrasound as a transcutaneous immunization adjuvant. Vaccine 23, 3800-3807 (2005).
106. Fang JY, Lee WR, Shen SC, Wang HY, Fang CL, Hu CH. Transdermal delivery of macromolecules by erbium:YAG laser. J. Cont. Rel. 100, 75-85 (2004).
107. Lee S, McAuliffe DJ, Flotte TJ, Kollias N, Doukas AG. Photomechanical transdermal delivery: the effect of laser confinement. Lasers Surg. Med. 28, 344-347 (2001).
108. Lee WR, Shen SC, Liu CR, Fang CL, Hu CH, Fang JY. Erbium: YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study. J. Cont. Rel. 115, 344-353 (2006).
109. Jacques SL, McAuliffe DJ, Blank IH, Parrish JA. Controlled removal of human stratum corneum by pulsed laser. J. Invest. Dermatol. 88, 88-93 (1987).
110. Frech SA, DuPont HL, Bourgeois AL et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a Phase II, randomised, double-blind, placebo-controlled field trial. Lancet 371, 2019-2025 (2008). • Phase II clinical trial showing immunization via skin abrasion followed by application of a patch containing heat-labile toxin from Escherichia coli.
111. Etchart N, Hennino A, Friede M et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 25, 6891-6899 (2007).
112. Baxter J, Mitragotri S. Needle-free liquid jet injections: mechanisms and applications. Exp. Rev. Med. Dev. 3, 565-574 (2006).
113. Dean HJ, Chen DX. Epidermal powder immunization against influenza. Vaccine 23, 681-686 (2004).
114. Chen DX, Endres R, Maa YF et al. Epidermal powder immunization of mice and monkeys with an influenza vaccine. Vaccine 21, 2830-2836 (2003).
115. Hoffman PN, Abuknesha RA, Andrews NJ, Samuel D, Lloyd JS. A model to assess the infection potential of jet injectors used in mass immunisation. Vaccine 19, 4020-4027 (2001).
116. Gill HS, Prausnitz MR. Coated microneedles for transdermal delivery. J. Control. Release 117, 227-237 (2007).
117. Widera G, Johnson J, Kim L et al. Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. Vaccine 24, 1653-1664 (2006).
118. Gill HS, Prausnitz MR. Coating formulations for microneedles. Pharma. Res. 24, 1369-1380 (2007).
119. Miyano T, Tobinaga Y, Kanno T et al. Sugar micro needles as transdermic drug delivery system. Biomed. Microdev. 7, 185-188 (2005).
120. Sullivan SP, Murthy N, Prausnitz MR. Minimally invasive protein delivery with rapidly dissolving polymer microneedles. Adv. Mater. 20, 933-938 (2008).
121. Laurent PE, Bonnet S, Alchas P et al. Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system. Vaccine 25, 8833-8842 (2007).
122. Alarcon JB, Hartley AW, Harvey NG, Mikszta JA. Preclinical evaluation of microneedle technology for intradermal delivery of influenza vaccines. Clin. Vacc. Immunol. 14, 375-381 (2007).
123. Mikszta JA, Dekker JP, Harvey NG et al. Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine. Infect. Immun. 74, 6806-6810 (2006).
124. Laurent A, Mistretta F, Bottigioli D et al. Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines. Vaccine 25, 6423-6430 (2007).